Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Allotment
Allotment of Shares30-01-2024
30-01-2024
Strides Pharma Science Ltd - 532531 - Intimation Under Regulation 30 Of SEBI LODR - Corporate Guarantee On Behalf Of Stelis
Intimation under Regulation 30 of SEBI LODR - Corporate Guarantee on behalf of Stelis30-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Change in Directorate
Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company effective February 1, 202430-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides reports strong Q3FY24 Revenue and EBITDA30-01-2024
Strides Pharma Science Ltd - 532531 - Outcome Of Board Meeting - Un-Audited Financial Results (Standalone & Consolidated) For Quarter And Nine Months Ended December 31, 2023
Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 202330-01-2024
Strides Pharma gains after arm receives USFDA nod for Pregabalin capsule
The Pregabalin capsule is used in the treatment of fibromyalgia, is a chronic health condition that causes pain and tenderness throughout the body29-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Strides receives USFDA approval for Pregabalin Capsules25-01-2024
Strides Pharma Science Ltd - 532531 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Haresh Dave & Karesh Dave23-01-2024
Strides Pharma Science Ltd - 532531 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Earnings Call for discussion of un-audited financial results for the quarter and nine months ended December 31, 202323-01-2024
Strides Pharma Science Ltd - 532531 - Board Meeting Intimation for Announcement Of Board Meeting Under Regulation 29 Of SEBI Listing Regulations
Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, January 30, 2024, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2023, amongst other matters. Further, as per provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company.22-01-2024